Literature DB >> 30333114

Making the change to area under the curve-based vancomycin dosing.

Emily L Heil1, Kimberly C Claeys2, Ryan P Mynatt3, Teri L Hopkins4, Karrine Brade5, Ian Watt6, Michael J Rybak7, Jason M Pogue8.   

Abstract

Entities:  

Keywords:  S. aureus; area under the curve; minimum inhibitory concentration; pharmacodynamics; pharmacokinetics; vancomycin

Mesh：

Substances：

Year:  2018        PMID： 30333114     DOI： 10.2146/ajhp180034

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN： 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  18 in total

1.  Should Therapeutic Monitoring of Vancomycin Based on Area under the Curve Become Standard Practice for Patients with Confirmed or Suspected Methicillin-Resistant Staphylococcus aureus Infection?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2020-06-01

2.  Point-Counterpoint: Should Clinical Microbiology Laboratories Report Vancomycin MICs?

Authors:  Sara L Revolinski; Christopher D Doern
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

3.  Gap Analysis for the Conversion to Area Under the Curve Vancomycin Monitoring in a Small Rural Hospital.

Authors:  Jennifer L Cole
Journal:  Fed Pract       Date:  2020-06

4.  Optimizing Vancomycin Dosing and Monitoring in Neonates and Infants Using Population Pharmacokinetic Modeling.

Authors:  Praneeth Jarugula; Ayse Akcan-Arikan; Flor Munoz-Rivas; Brady S Moffett; Vijay Ivaturi; Danielle Rios
Journal:  Antimicrob Agents Chemother       Date:  2022-03-16       Impact factor: 5.938

5.  Methods of Therapeutic Drug Monitoring to Guide Vancomycin Dosing Regimens: Trough Concentration versus Ratio of Area Under the Curve to Minimum Inhibitory Concentration.

Authors:  Ariane Du Sault; Marc Parent; Chantale Simard
Journal:  Can J Hosp Pharm       Date:  2022-04-04

6.  Vancomycin dosing required to achieve a therapeutic level in children post-surgical correction of congenital heart disease.

Authors:  Yousif S Alakeel; Ghadah A Alanazi; Bushra S Alawbathani; Kadi I Alshutwi; Yazeed S Alahmed
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

Review 7.  An Update on Population Pharmacokinetic Analyses of Vancomycin, Part I: In Adults.

Authors:  Abdullah Aljutayli; Amélie Marsot; Fahima Nekka
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

8.  Therapeutic Drug Monitoring of Vancomycin in Adult Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia or Pneumonia.

Authors:  Ryan Marko; Julia Hajjar; Vanessa Nzeribe; Michelle Pittman; Vincent Deslandes; Nadia Sant; Juthaporn Cowan; Kwadwo Kyermentang; Tim Ramsay; Sheryl Zelenitsky; Salmaan Kanji
Journal:  Can J Hosp Pharm       Date:  2021

9.  Vancomycin Area Under the Curve to Predict Timely Clinical Response in the Treatment of Methicillin-resistant Staphylococcus aureus Complicated Skin and Soft Tissue Infections.

Authors:  Sara Alosaimy; Kyle P Murray; Evan J Zasowski; Taylor Morrisette; Abdalhamid M Lagnf; Thomas P Lodise; Michael J Rybak
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

10.  Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis.

Authors:  Sara Alosaimy; Noor L Sabagha; Abdalhamid M Lagnf; Evan J Zasowski; Taylor Morrisette; Sarah C J Jorgensen; Trang D Trinh; Ryan P Mynatt; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2020-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.